Krystal Biotech (KRYS) Net Cash Flow (2016 - 2026)

Krystal Biotech has disclosed Net Cash Flow across 11 years of filings, most recently posting $6.3 million for Q1 2026.

• Net Cash Flow for Q1 2026 came in at $6.3 million, up 117.48% year-over-year; the trailing twelve-month figure through Mar 2026 was $193.8 million (up 489.37% YoY), and the FY2025 annual result was $151.2 million, up 1262.27% from the prior year.
• Net Cash Flow came in at $6.3 million for Q1 2026 at Krystal Biotech, down from $104.3 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $135.1 million in Q2 2023 to a low of -$71.9 million in Q1 2022.
• The 5-year median for Net Cash Flow is -$12.9 million (2024), against an average of $9.5 million.
• Peak annual rise in Net Cash Flow reached 466.0% in 2025, while the deepest fall reached 7486.15% in 2025.
• Krystal Biotech's Net Cash Flow stood at -$24.5 million in 2022, then soared by 39.62% to -$14.8 million in 2023, then slumped by 92.97% to -$28.5 million in 2024, then jumped by 466.0% to $104.3 million in 2025, then slumped by 93.92% to $6.3 million in 2026.
• The last three Net Cash Flow figures came in at $6.3 million (Q1 2026), $104.3 million (Q4 2025), and $39.1 million (Q3 2025), per Business Quant data.